CytomX Therapeutics
Develops tumor-localized, conditionally activated oncology biologics through its PROBODY platform.
$3.20
After-hours close−0.01 (−0.47%)
At close$3.22(−5.99%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 88.73%193.17M sharesInsiders 1.42%3.09M sharesOther 9.85%21.44M shares
Shares outstanding 217.70M · Float 173.12M · 79.5% free float
Institutions13F, as of Mar 31, 2026
191 holders · 193.17M shares · 79 new positions · 137 increased · 29 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 31.96M | 14.68% | +7.27M | May 15, 2026 |
| Kynam Capital Management, LP | 15.01M | 6.90% | +6.05M | May 15, 2026 |
| Bank of America Corp /DE/ | 10.20M | 4.69% | +9.33M | May 18, 2026 |
| Perceptive Advisors LLC | 10.10M | 4.64% | +418.6K | May 29, 2026 |
| VR Adviser, LLC | 9.98M | 4.59% | −5.58M | May 15, 2026 |
| Vanguard Capital Management LLC | 8.73M | 4.01% | +8.73Mnew | May 15, 2026 |
| Point72 Asset Management, L.P. | 7.88M | 3.62% | +2.69M | May 15, 2026 |
| State Street Corp | 5.66M | 2.60% | +522.5K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.60% | 24.69M | 13G | Feb 5, 2026 ↗ |
| BlackRock, Inc. | 7.60% | 16.55M | 13G | Jul 27, 2026 ↗ |
| Bank of America Corp /DE/ | 7.00% | 15.13M | 13G | Aug 3, 2026 ↗ |
| Kynam Capital Management, LP | 6.90% | 0 | 13G | May 15, 2026 ↗ |
| Longitude Capital Partners V, LLC | 5.70% | 12.46M | 13G | May 15, 2026 ↗ |
| Point72 Asset Management, L.P. | 5.00% | 10.86M | 13G | Apr 16, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Sean A. McCarthy | director, officer: CEO | 2.07M | 0.95% | Mar 19, 2026 |
| Marcia Belvin | officer: SVP, Chief Scientific Officer | 300.8K | 0.14% | Mar 19, 2026 |
| Christopher Ogden | officer: Chief Financial Officer | 295.3K | 0.14% | Jun 17, 2026 |
| Yu-Waye Chu | officer: Chief Medical Officer | 189.4K | 0.09% | Mar 19, 2026 |
| Lloyd A. Rowland | officer: General Counsel | 120.6K | 0.06% | Mar 20, 2025 |
| Alejandra Carvajal | officer: Chief Legal Officer | 100.0K | 0.05% | Aug 5, 2026 |
| Rachael Lester | officer: Chief Business Officer | 20.0K | 0.01% | Feb 4, 2026 |
6 ten-percent owners hold 7.24M shares by Form 4, outside the officers-and-directors figure above · 14 people have not refiled in the last 18 months (6.31M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogdenofficer: Chief Financial Officer | Sale | 1,624 | $3.05 | 295,324 |
| Mar 17, 2026 | Christopher Ogdenofficer: Chief Financial Officer | Sale | 19,323 | $6.42 | 296,948 |
| Mar 17, 2026 | Marcia Belvinofficer: SVP, Chief Scientific Officer | Sale | 31,492 | $6.42 | 300,760 |
| Mar 17, 2026 | Sean A. McCarthydirector, officer: CEO | Sale | 118,969 | $6.42 | 1,078,922 |
| Mar 17, 2026 | Yu-Waye Chuofficer: Chief Medical Officer | Sale | 21,279 | $6.42 | 189,446 |
| Nov 6, 2025 | Sean A. McCarthydirector, officer: CEO | Sale | 101,793 | $4.54 | 987,891 |
CongressHouse and Senate disclosures
Not reported.